The OLE data is incrementally positive for safety but does not salvage the failed PALISADE-3 randomized trial. The stock's next catalyst is PALISADE-4 topline data in Q2 2026 — a binary event that will determine whether fasedienol has a viable path to an NDA. Monitor for PALISADE-4 results and any financing needs given the small market cap.
Price Chart
Executive Summary
Vistagen announced preliminary positive safety and exploratory efficacy data from the open-label extension (OLE) of its PALISADE-3 Phase 3 study of fasedienol for social anxiety disorder. The OLE data showed fasedienol was well-tolerated over up to 12 months of as-needed use, with clinically relevant improvements on anxiety scales over four months. However, the randomized, placebo-controlled portion of PALISADE-3 failed its primary endpoint in December 2025, so this open-label data does not change the drug's regulatory path and the stock's binary risk profile remains tied to the upcoming PALISADE-4 topline results.
Key Facts
- PALISADE-3 OLE safety data (n=341): fasedienol well-tolerated up to 12 months, 2.6% discontinuation rate due to AEs, no drug-related SAEs.
- Exploratory efficacy: LSAS mean improvement of 25.4 points at Month 4 (n=228, 56% had ≥20-point improvement); SPIN mean improvement of 12.4 points at Month 4 (n=228, 55% had ≥10-point improvement).
- The randomized, double-blind portion of PALISADE-3 failed its primary endpoint in December 2025 — no treatment difference vs placebo on SUDS.
- PALISADE-4 topline data expected in Q2 2026; Phase 2 Repeat Dose Study topline expected in Q3 2026.
- Market cap is ~$27M with 0% analyst bullish consensus (7 Hold, 3 Sell/Strong Sell).
Financial Impact
No financial figures disclosed in filing. Company is pre-revenue clinical-stage biotech with $27M market cap.
Risk Factors
- PALISADE-4 may also fail to meet its primary endpoint, mirroring PALISADE-3's failure.
- Company may need to raise capital to fund ongoing operations, causing dilution.
- Even if PALISADE-4 succeeds, FDA may require additional trials before accepting an NDA.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-033883 |
| Document: vtgn-20260512.htm | 0001628280-26-033883 |
| Document: 0001628280-26-033883-index-headers.html | 0001628280-26-033883 |
| Document: 0001628280-26-033883-index.html | 0001628280-26-033883 |
| Document: 0001628280-26-033883.txt | 0001628280-26-033883 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 14, 2026 7w ago | 8-K | $0.2676 $0.2432 | ▲ +9.12% | ▲ +7.13% | $0.2847 (−6.39%) |
Aug 14, 2026 7w ago | Press Release | $0.2676 $0.2432 | ▼ −9.12% | ▼ −7.13% | $0.2847 (+6.39%) |
Jul 31, 2026 9w ago | 8-K | $0.2410 $0.2529 | ▲ +4.94% | ▲ +1.95% | $0.2847 (+18.13%) |
Jun 30, 2026 13w ago | 8-K | $0.2260 $0.2302 | ▼ −1.86% | ▼ −2.89% | $0.2847 (−25.97%) |
Jun 17, 2026 15w ago | 8-K | $0.6702 $0.2400 | ▼ −64.19% | ▼ −64.72% | $0.2847 (−57.52%) |
Jun 15, 2026 15w ago | 8-K | $0.6900 $0.2461 | ▼ −64.33% | ▼ −64.53% | $0.2847 (−58.74%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.5731 $0.2492 | ▼ −56.52% | ▼ −58.41% | $0.2847 (−50.32%) |
Jun 9, 2026 16w ago | 8-K | $0.5351 $0.2492 | ▼ −53.43% | ▼ −57.05% | $0.2847 (−46.79%) |
May 19, 2026 19w ago | 8-K | $0.6400 $0.6702 | ▲ +4.72% | ▲ +3.98% | $0.2847 (−55.52%) |
May 12, 2026 20w ago | 8-K | $0.6200 $0.5400 | ▼ −12.90% | ▼ −11.18% | $0.2847 (−54.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access